NO942072L - Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks - Google Patents
Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriksInfo
- Publication number
- NO942072L NO942072L NO942072A NO942072A NO942072L NO 942072 L NO942072 L NO 942072L NO 942072 A NO942072 A NO 942072A NO 942072 A NO942072 A NO 942072A NO 942072 L NO942072 L NO 942072L
- Authority
- NO
- Norway
- Prior art keywords
- growth factor
- fibrosis
- accumulation
- extracellular matrix
- inhibition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Abstract
Fremgangsmåte for å behandle eller stanse utviklingen av sykdomstil- stander kjennetegnet ved en akkumuler- ing av ekstracellulære matriksbestand- deler ved å tilføre et middel som undertrykker aktiviteten av transfor- merende vekstfaktor p (TGF-p), en peptidvekstfaktor som er anabolsk og fører til fibrose og angiogenese. Syk- domstilstander som kan behandles på denne måte omfatter de forskjellige fibrotiske sykdomstilstander som fibrotisk cancer, lungefibrose, arteriosklerose, .postmyokardinfarkt, hjertefibrose, postangioplastisk restenose, renal interstitiell fibrose, arrdannelse og diabetisk nefropati. Fremgangsmåter for behandling .av diabetes og farmasøytiske preparater som er anvendbare i slike fremgangs- måter beskrives også.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80328591A | 1991-12-04 | 1991-12-04 | |
PCT/US1992/010550 WO1993010808A1 (en) | 1991-12-04 | 1992-12-04 | INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX |
Publications (2)
Publication Number | Publication Date |
---|---|
NO942072D0 NO942072D0 (no) | 1994-06-03 |
NO942072L true NO942072L (no) | 1994-08-03 |
Family
ID=25186123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO942072A NO942072L (no) | 1991-12-04 | 1994-06-03 | Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0616536B1 (no) |
JP (2) | JP3854307B2 (no) |
AT (1) | ATE177644T1 (no) |
AU (2) | AU670770B2 (no) |
CA (1) | CA2124591A1 (no) |
DE (1) | DE69228700T2 (no) |
DK (1) | DK0616536T3 (no) |
FI (1) | FI942622A (no) |
NO (1) | NO942072L (no) |
WO (1) | WO1993010808A1 (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE406909T1 (de) * | 1993-05-13 | 2008-09-15 | Poniard Pharmaceuticals Inc | Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind |
US5453492A (en) * | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
ATE315939T1 (de) * | 1993-11-19 | 2006-02-15 | Univ Sydney | Verfahren zur prophylaxe oder kontrolle des katarakts |
EP0754058B1 (en) * | 1994-03-29 | 1999-11-03 | The Victoria University Of Manchester | Wound healing |
US5824655A (en) * | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
DE19613691A1 (de) * | 1996-04-05 | 1997-10-09 | Boehringer Ingelheim Int | Arzneimittel für die Behandlung von Tumorerkrankungen |
AU1826799A (en) * | 1998-01-09 | 1999-07-26 | University Of Utah, The | Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by tgfbeta using renin inhibitors |
US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
AU2008200019B2 (en) * | 1999-01-05 | 2009-10-08 | American National Red Cross | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
EP1140041A2 (en) * | 1999-01-05 | 2001-10-10 | University of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
US6864236B1 (en) | 1999-11-18 | 2005-03-08 | Brown University Research Foundation | Biglycan and related therapeutics and methods of use |
US7612038B2 (en) | 1999-11-18 | 2009-11-03 | Brown University | Biglycan and related therapeutics and methods of use |
GB0102673D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
DE60230877D1 (de) | 2001-08-15 | 2009-03-05 | Univ Brown Res Found | Behandlung von muskeldystrophien und verwandter erkrankungen |
JP4564261B2 (ja) * | 2002-01-22 | 2010-10-20 | ジェンザイム、コーポレーション | 慢性的移植片拒絶反応の治療と予防のためのTGF−β拮抗薬の使用 |
WO2004075917A1 (ja) * | 2003-02-28 | 2004-09-10 | Toudai Tlo, Ltd. | 器官または組織の線維化抑制剤 |
EP1948675B1 (en) | 2005-10-25 | 2014-07-30 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
EP2230252A1 (en) | 2006-03-13 | 2010-09-22 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
EP1983345A1 (en) * | 2007-04-17 | 2008-10-22 | Roche Diagnostics GmbH | Means and method for assessing the risk of a cardiac intervention in patients suffering from a stable coronary heart disease based on GDF-15 |
HUE027831T2 (en) | 2010-03-12 | 2016-11-28 | Genzyme Corp | Combination therapy for breast cancer |
ES2691443T3 (es) | 2010-05-17 | 2018-11-27 | Brown University | Mutantes de biglicano y agentes terapéuticos relacionados y métodos de uso |
WO2012092299A1 (en) | 2010-12-27 | 2012-07-05 | Brown University | Therapeutic and diagnostic methods involving biglycan and utrophin |
CA2823154A1 (en) | 2010-12-27 | 2012-07-05 | Lsip, Llc | Ips cells and method for generating same |
KR102051014B1 (ko) | 2011-06-03 | 2019-12-04 | 조마 테크놀로지 리미티드 | Tgf-베타에 특이적인 항체 |
EP2799537B1 (en) | 2011-12-28 | 2021-09-22 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
EP3064222B1 (en) | 2013-10-31 | 2020-10-21 | Kyoto Prefectural Public University Corporation | Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium |
US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
WO2017223268A1 (en) * | 2016-06-22 | 2017-12-28 | Yale University | COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi) |
JP7109039B2 (ja) | 2016-07-07 | 2022-07-29 | 国立大学法人千葉大学 | 抗線維症剤およびリン酸化Smad核内移行阻害剤 |
WO2019143219A1 (ko) * | 2018-01-22 | 2019-07-25 | 고려대학교 산학협력단 | 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물 |
KR102141125B1 (ko) * | 2018-01-22 | 2020-08-05 | 고려대학교 산학협력단 | 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물 |
US20220160821A1 (en) * | 2019-04-11 | 2022-05-26 | Korea University Research And Business Foundation | Pharmaceutical composition for preventing or treating obesity containing biglycan as active ingredient |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004748A1 (en) * | 1989-09-29 | 1991-04-18 | La Jolla Cancer Research Foundation | INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX |
WO1991010727A1 (en) * | 1990-01-22 | 1991-07-25 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors |
-
1992
- 1992-12-04 DE DE69228700T patent/DE69228700T2/de not_active Expired - Lifetime
- 1992-12-04 EP EP93900930A patent/EP0616536B1/en not_active Expired - Lifetime
- 1992-12-04 JP JP51038393A patent/JP3854307B2/ja not_active Expired - Lifetime
- 1992-12-04 AU AU32429/93A patent/AU670770B2/en not_active Expired
- 1992-12-04 DK DK93900930T patent/DK0616536T3/da active
- 1992-12-04 WO PCT/US1992/010550 patent/WO1993010808A1/en active IP Right Grant
- 1992-12-04 AT AT93900930T patent/ATE177644T1/de not_active IP Right Cessation
- 1992-12-04 CA CA002124591A patent/CA2124591A1/en not_active Abandoned
-
1994
- 1994-06-03 FI FI942622A patent/FI942622A/fi not_active Application Discontinuation
- 1994-06-03 NO NO942072A patent/NO942072L/no unknown
-
1996
- 1996-10-25 AU AU70518/96A patent/AU7051896A/en not_active Abandoned
-
2003
- 2003-10-31 JP JP2003373712A patent/JP2004043507A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2124591A1 (en) | 1993-06-10 |
AU3242993A (en) | 1993-06-28 |
DE69228700D1 (de) | 1999-04-22 |
JPH07504650A (ja) | 1995-05-25 |
DE69228700T2 (de) | 1999-09-09 |
FI942622A (fi) | 1994-07-27 |
JP3854307B2 (ja) | 2006-12-06 |
WO1993010808A1 (en) | 1993-06-10 |
FI942622A0 (fi) | 1994-06-03 |
AU7051896A (en) | 1997-01-16 |
ATE177644T1 (de) | 1999-04-15 |
NO942072D0 (no) | 1994-06-03 |
EP0616536A1 (en) | 1994-09-28 |
JP2004043507A (ja) | 2004-02-12 |
EP0616536B1 (en) | 1999-03-17 |
AU670770B2 (en) | 1996-08-01 |
DK0616536T3 (da) | 1999-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO942072D0 (no) | Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks | |
El-sherif et al. | Quinidine-induced long QTU interval and torsade de pointes: role of bradycardia-dependent early afterdepolarizations | |
ATE193541T1 (de) | Insulinotropes hormon | |
JPS6429308A (en) | Treatment of hyperhydrosis, psoriasis and wrinkle | |
DE69738615D1 (de) | Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt | |
NO921119L (no) | Inhibering av transformerende vekstfaktor beta for aa forhindre akkumulering av ekstracellulaer matriks | |
EP1123129A4 (en) | SYSTEMS AND COMPOUNDS FOR ADMINISTRATION OF MEDICINE IN INTERSTITIAL REGIONS OF MYOCARD | |
EA199900861A1 (ru) | Усеченные белки, родственные фактору роста эндотелия сосудов | |
ES2054995T3 (es) | Nuevos derivados del acido benzoico y acido fenilacetico, su obtencion y empleo como medicamentos. | |
RU94013439A (ru) | Гетероциклические соединения, способ их получения, фармацевтическая композиция и способ лечения | |
DE2315801A1 (de) | 2-alkyl-3-acyl-pyrazolo-eckige klammer auf 1,5-a eckige klammer zu-pyridine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate | |
CA2997131C (en) | Long-acting adrenomedullin derivative | |
CY1110445T1 (el) | Γονιδιακη θεραπεια για διαβητικη ισχαιμικη ασθενεια | |
PL374016A1 (en) | The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases | |
ATE378051T1 (de) | Nicotinrezeptor-agonisten zur behandlung von entzündlichen lungenerkrankungen | |
Payne et al. | Blood vessel formation during tail regeneration in the leopard gecko (Eublepharis macularius): the blastema is not avascular | |
Brooks et al. | Inhibition of gastric acid secretion in man by peptide analogues of cholecystokinin | |
NZ516336A (en) | Thiophene A2A receptor agonists | |
WO2022030580A1 (ja) | 長時間作用型新規アドレノメデュリン誘導体、その製造方法及びその医薬用途 | |
EA200400428A1 (ru) | Применение лютеинизирующего гормона при контролируемой гиперстимуляции яичников | |
Kaltenbach et al. | Treatment of hypertrophic cardiomyopathy: Relation to pathological mechanisms | |
Plack et al. | Complete heart block developing during aortic valvuloplasty | |
JP3195793B2 (ja) | 成長因子の組成、調製および使用 | |
Lozano et al. | Reentrant tachycardia: participation of the distal AV conduction system | |
Le Coniat et al. | Chronic in Vivo Animal Data on a Wireless Systolic Synchronized Mini-Cardiac Pump |